![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: ADAMTS2 |
Gene summary for ADAMTS2 |
![]() |
Gene information | Species | Human | Gene symbol | ADAMTS2 | Gene ID | 9509 |
Gene name | ADAM metallopeptidase with thrombospondin type 1 motif 2 | |
Gene Alias | ADAM-TS2 | |
Cytomap | 5q35.3 | |
Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | O95450 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
9509 | ADAMTS2 | ATC12 | Human | Thyroid | ATC | 1.72e-28 | 6.12e-01 | 0.34 |
9509 | ADAMTS2 | ATC13 | Human | Thyroid | ATC | 3.04e-38 | 6.43e-01 | 0.34 |
9509 | ADAMTS2 | ATC2 | Human | Thyroid | ATC | 2.49e-06 | 6.31e-01 | 0.34 |
9509 | ADAMTS2 | ATC4 | Human | Thyroid | ATC | 1.32e-34 | 7.35e-01 | 0.34 |
9509 | ADAMTS2 | ATC5 | Human | Thyroid | ATC | 8.04e-38 | 7.08e-01 | 0.34 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Thyroid | ![]() | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis | ||
PTC: Papillary thyroid cancer |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Oral cavity | OSCC | ![]() |
Oral cavity | LP | ![]() |
Oral cavity | EOLP | ![]() |
Oral cavity | NEOLP | ![]() |
Esophagus | HGIN | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:003019812 | Thyroid | ATC | extracellular matrix organization | 152/6293 | 301/18723 | 8.63e-10 | 2.24e-08 | 152 |
GO:004306212 | Thyroid | ATC | extracellular structure organization | 152/6293 | 302/18723 | 1.17e-09 | 2.94e-08 | 152 |
GO:004522912 | Thyroid | ATC | external encapsulating structure organization | 152/6293 | 304/18723 | 2.11e-09 | 5.08e-08 | 152 |
GO:003019911 | Thyroid | ATC | collagen fibril organization | 43/6293 | 61/18723 | 4.24e-09 | 9.57e-08 | 43 |
GO:003032321 | Thyroid | ATC | respiratory tube development | 93/6293 | 181/18723 | 5.67e-07 | 8.02e-06 | 93 |
GO:003032421 | Thyroid | ATC | lung development | 90/6293 | 177/18723 | 1.53e-06 | 1.88e-05 | 90 |
GO:006054121 | Thyroid | ATC | respiratory system development | 100/6293 | 203/18723 | 2.66e-06 | 3.08e-05 | 100 |
GO:0051604110 | Thyroid | ATC | protein maturation | 136/6293 | 294/18723 | 4.00e-06 | 4.42e-05 | 136 |
GO:00329633 | Thyroid | ATC | collagen metabolic process | 52/6293 | 104/18723 | 3.94e-04 | 2.38e-03 | 52 |
GO:001648515 | Thyroid | ATC | protein processing | 100/6293 | 225/18723 | 4.39e-04 | 2.62e-03 | 100 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ADAMTS2 | SNV | Missense_Mutation | rs766939294 | c.2917N>A | p.Glu973Lys | p.E973K | O95450 | protein_coding | tolerated(0.51) | benign(0.137) | TCGA-A2-A0SY-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | arimidex | SD |
ADAMTS2 | SNV | Missense_Mutation | rs760609413 | c.3163C>T | p.Arg1055Trp | p.R1055W | O95450 | protein_coding | deleterious(0.02) | benign(0.232) | TCGA-A2-A0YE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Taxotere | SD |
ADAMTS2 | SNV | Missense_Mutation | novel | c.2555A>G | p.Asp852Gly | p.D852G | O95450 | protein_coding | deleterious(0.05) | benign(0.35) | TCGA-A7-A0CJ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
ADAMTS2 | SNV | Missense_Mutation | novel | c.1718N>A | p.Cys573Tyr | p.C573Y | O95450 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A7-A3J1-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | anastrazole | SD |
ADAMTS2 | SNV | Missense_Mutation | c.484N>A | p.Ala162Thr | p.A162T | O95450 | protein_coding | tolerated(1) | benign(0.007) | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
ADAMTS2 | SNV | Missense_Mutation | c.3013N>A | p.Ala1005Thr | p.A1005T | O95450 | protein_coding | tolerated(0.53) | benign(0.003) | TCGA-AQ-A54N-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
ADAMTS2 | SNV | Missense_Mutation | c.3616G>C | p.Glu1206Gln | p.E1206Q | O95450 | protein_coding | deleterious_low_confidence(0.03) | probably_damaging(0.994) | TCGA-BH-A18U-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
ADAMTS2 | SNV | Missense_Mutation | c.3033N>G | p.Ile1011Met | p.I1011M | O95450 | protein_coding | tolerated(0.23) | benign(0.309) | TCGA-BH-A1FN-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |
ADAMTS2 | SNV | Missense_Mutation | novel | c.3577N>G | p.Gln1193Glu | p.Q1193E | O95450 | protein_coding | deleterious_low_confidence(0.01) | benign(0.024) | TCGA-D8-A1XZ-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | tamoxiphen+anastrozolum | SD |
ADAMTS2 | SNV | Missense_Mutation | rs753921602 | c.2071N>T | p.Arg691Cys | p.R691C | O95450 | protein_coding | deleterious(0) | probably_damaging(0.956) | TCGA-E9-A1R4-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | 5-fluorouracil | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |